A trial of a new treatment for patients with pancreatic cancer was presented at the Annual Congress of the Asco (American society for clinical oncology) in Chicago (United States). This treatment, called Lynparza, is aimed more specifically at patients with a genetic form of pancreatic cancer caused by a mutation in the BRCA1 or BRCA2 genes.
1 in 4 patients have not experienced disease progression
Mutation of these genes is most often associated with the risk of breast canceror from Uterus cancer. But the genetic mutation is also implicated in pancreatic cancer, one of the cancers the most difficult to treat. Faced with Asco, the laboratory AstraZeneca announced that, in a phase 3 trial, its drug had almost doubled the survival time of patients, without progression of their metastatic pancreatic cancer.
This disease progression-free survival time was a median of 7.4 months for patients treated with Lynparza compared to 3.8 months for those taking placebo. In addition, 22% of patients receiving Lynparza did not experience disease progression after 2 years compared to 10% on placebo.
Cancer #pancreas is often diagnosed late, which has a significant impact on quality of life and leads to a poor prognosis. 80% of patients present at the metastatic stage. # ASCO19pic.twitter.com/9PGmRjjOs8
– AstraZeneca France (@AstraZenecaFR) June 2, 2019
Read also :
A new treatment for pancreatic cancer
Soon a simple blood test to diagnose pancreatic cancer?
